Associated Papers
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency.
Simoneau A et al.
Molecular Cancer Therapeutics, 2025
Structural and Biochemical Insights into the Mechanism of Action of the Clinical USP1 Inhibitor, KSQ-4279.
Rennie ML et al.
Journal of Medicinal Chemistry, 2024
Variety in the USP deubiquitinase catalytic mechanism.
Keijzer N et al.
Life Science Alliance, 2024
Cryo-EM reveals a mechanism of USP1 inhibition through a cryptic binding site.
Rennie ML et al.
Science Advances, 2022
Structural basis of FANCD2 deubiquitination by USP1-UAF1.
Rennie ML et al.
Nature Structural & Molecular Biology, 2021
Differential functions of FANCI and FANCD2 ubiquitination stabilize ID2 complex on DNA.
Rennie ML et al.
Embo Reports, 2020
Specificity for deubiquitination of monoubiquitinated FANCD2 is driven by the N-terminus of USP1.
Arkinson C et al.
Life Science Alliance, 2018
Mechanism of Ubiquitination and Deubiquitination in the Fanconi Anemia Pathway.
van Twest S et al.
Molecular Cell, 2017
Serine phosphorylation is critical for the activation of ubiquitin-specific protease 1 and its interaction with WD40-repeat protein UAF1.
Villamil MA et al.
Biochemistry, 2012
Select a paper to view details